AmplifiDx, founded on the principles of scientific excellence and a dedication to improving patient outcomes, is a trailblazing player in the realm of molecular diagnostics. The company specializes in developing molecular diagnostic assays that leverage the power of nucleic acid amplification technologies. With a mission to provide healthcare professionals with reliable and rapid diagnostic tools, AmplifiDx is at the forefront of addressing the evolving needs of modern medicine.

AmplifiDx’s research and development of the AmplifiDxTM DX-100, a compact and affordable instrument designed for point-of-care testing is progressing human healthcare forward, providing a unique and valuable tool for managing patients with infectious diseases ina physicians clinic.

AmplifiDx has been working with FreeMind Group since 2021 in order to begin its non-dilutive funding journey to fund its important research into molecular biology for diagnostic purposes.

AmplifiDx stands as a shining example of how innovation in diagnostics can have a profound impact on patient care. By combining cutting-edge technologies with a dedication to precision medicine, AmplifiDx is paving the way for a healthier and more informed future.

AmplifiDx is honored to be recognized by Freemind for our pursuit of non-dilutive funding. These grants have significantly de-risked our innovative molecular point-of-care platform.

At the heart of this achievement lies our partnership with Freemind, who have played an instrumental role. They’ve been pivotal in nurturing product ideas, crafting assay menus with compelling clinical utility and societal impact, and weaving our narrative. Moreover, our grant applications have seamlessly integrated with our business strategy, creating an interactive synergy that propels our growth.

This honor is a testament to our commitment to innovation and making a substantial impact in the diagnostics field. Thank you, Freemind, for being an integral part of our journey!

AmplifiDx FreeMind Elite Presentation at NDFS 2024